10th Mar 2022 20:31
(Alliance News) Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Says phase 1 data presented at Virtual Interstitial Lung Disease Drug Development summit shows novel anti-fibrotic drug candidate, RXC007, possesses excellent safety and pharmacokinetic profile in both the single and multiple dose phase. No adverse events were observed following single doses of 2-70 milligrams, dosed once or twice in a day and no serious adverse events were observed in the multiple dose phase, dosed at 50mg twice daily for 14 days, with only transient, reversible mild adverse events observed, it says.
Current stock price: 73.10 pence
Year-to-date change: up 16%
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
REDX.L